A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
about
Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor MicroenvironmentExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesWhole Tumor Antigen Vaccines: Where Are We?Role of dendritic cell subsets in immunity and their contribution to noninfectious uveitisTumor infiltrating lymphocytes in ovarian cancerTargeting the tumor vasculature to enhance T cell activityDendritic cell-based vaccine efficacy: aiming for hot spotsTumor cell lysates as immunogenic sources for cancer vaccine designOxidation by neutrophils-derived HOCl increases immunogenicity of proteins by converting them into ligands of several endocytic receptors involved in antigen uptake by dendritic cells and macrophagesTherapeutic cancer vaccines and combination immunotherapies involving vaccinationDCVax®-L--developed by Northwest BiotherapeuticsThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?Immunotherapeutic approaches to ovarian cancer treatment.TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Opportunities in immunotherapy of ovarian cancer.The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.Dendritic cells in cancer immunotherapy clinical trials: are we making progress?Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.Ovarian cancer biology and immunotherapy.Dendritic cell-based vaccine research against cancer.Potential approaches for more successful dendritic cell-based immunotherapy.Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Understanding dendritic cell immunotherapy in ovarian cancer.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.In vitro and in vivo antitumor effects of 50 to 100-KDa components from B16 melanoma culture supernatant.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.Dendritic cells based immunotherapy.Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Mechanisms regulating T-cell infiltration and activity in solid tumors.Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q26745898-5FB81F37-B9B8-4446-98D5-4F8CB5DEEDECQ26772715-194C7591-721A-4A2A-92B1-B1290678D892Q26783866-58364EAC-9F92-4214-99CB-8328687522FBQ26852793-DC486D04-51AC-406A-9B92-BBE33B6C337EQ27021878-965700A3-273B-4309-A042-8BDAC71F0D7CQ27026329-60ADEAC4-D4F4-45E9-BBD8-09B97A033055Q28082680-02DB03C4-1A20-4DFD-971C-E193CC5B5F1EQ28083469-78F22955-FA84-4813-BD6B-97E786BA8F5AQ28391399-30E59ADA-FBAC-4D53-9EF1-8E136677599BQ28397609-EF143E9E-A700-431B-A25D-AA54B673D4CDQ30875456-F3510C63-33DF-4B0B-85CE-513B00850109Q33815087-977BA8C2-765E-4F9F-A0DB-5505113EDEC0Q35213535-D511EE2E-6E8C-4C43-8D91-28AFD50FDB9AQ36343879-25DD085C-35C0-4336-A62F-C5D86F9E2BA7Q36710917-3FB79E41-04F9-45BA-9D4E-54E84275DACCQ36855245-521BCAF3-E1BB-49D7-AF9A-05E41ED6F2CDQ37180279-A0E633BC-295A-4929-9F5F-226074B3A0DDQ37389096-538CC2D9-72DB-4626-A643-33A3DAB9D605Q38208388-70D83FF9-FD7E-403A-A5A2-96D7F91FBC44Q38218761-2196CDA6-9546-4E9D-9F02-1AF9C00B5E11Q38281782-4115DF76-8349-4D1C-949E-D1BDDB580EF8Q38305650-1A98CDEE-2D7B-4DC6-926F-F6354FFA4EB3Q38602859-1A064F16-3028-4D1B-87C2-A9540D98A3CBQ38715211-3907A58E-5F5A-4F2A-AC8E-F874A7426AB0Q38808249-F7730898-F88C-46ED-8E98-E8AFE4ACA6E1Q39243064-EB48445B-D011-48D1-9159-140FD57518EDQ41205250-93ABFD2C-D2ED-4EA7-B373-AD07CD2D4C15Q41550106-5FF681DB-5041-4004-AD1B-0C61FBFD2300Q42378527-F1DAFDBE-2091-454A-93A3-E4EFF0EDA411Q42695076-BDF1A954-A00C-4A0A-B818-2076D362E741Q43043935-F2438017-7491-42BF-BD1A-43BB9BFFF1CFQ47151222-7720CE56-EB9E-4914-8ACA-B58CDC757C45Q49835172-035F508C-C26F-4E79-A103-2B8A190850E1Q50089395-8E0DABFD-DBF8-466E-8CE8-84BDAC5740F9Q50545957-9FDF9013-ADCD-457C-82F3-5E07A75E8756Q50566797-F9F4E5EC-1BE6-4AB8-AD9B-5751CDBA4414Q52647360-539E5C88-F8C8-490E-B634-2AF877230C5FQ52746279-C0E30C53-0641-41FF-958C-FAED9F1B8311Q53581193-2719F8E4-32EB-451B-A27E-FE3870D702CDQ54385315-97433875-5F63-4087-9F60-F8A2CFB2BCCF
P2860
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@ast
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@en
type
label
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@ast
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@en
prefLabel
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@ast
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@en
P2093
P2860
P1476
A dendritic cell vaccine pulse ...... munity: from bench to bedside.
@en
P2093
Andrea R Hagemann
Brian J Czerniecki
Bruce L Levine
Cheryl Lai-Lai Chiang
Daniel J Powell
Drew A Torigian
George Coukos
Gina M Mantia-Smaldone
Gregory T Motz
Harvey L Nisenbaum
P2860
P304
P356
10.1158/1078-0432.CCR-13-1185
P407
P577
2013-07-09T00:00:00Z